CD38 Gene Editing in CAR T and NK Cells for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD38-expressing cancers, such as multiple myeloma and lung cancer, are limited by immune suppression and tumor microenvironment modulation, and there is a need for more effective immunotherapy strategies targeting CD38.
Innovation Solution
Genetically modified T cells and NK cells with reduced or eliminated CD38 expression, equipped with chimeric antigen receptors (CARs) for CD38, are used in combination with CD38-targeting therapeutics like monoclonal antibodies to enhance cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy is used for CD38-expressing cancers, then treatment is provided, but immune suppression in the tumor microenvironment limits efficacy
Solution Approach 1:
The patent extracts and removes the harmful CD38 molecule from the tumor cells through genetic modification using CRISPR/Cas9 technology. By knocking out the CD38 gene in tumor cells, the invention eliminates the target that causes immune suppression and allows engineered T cells to effectively recognize and destroy the tumor cells without being suppressed by CD38-mediated mechanisms.
Solution Approach 2:
Instead of trying to enhance the immune system's ability to overcome suppression, the invention inverts the approach by modifying the tumor cells themselves to lack CD38 expression. This reversal transforms the problem from 'how to overcome immune suppression' to 'how to create tumor cells that are vulnerable to immune attack,' thereby resolving the efficacy limitation.
2Reliability
If CD38-targeting therapeutics are used, then cancer treatment is provided, but tumor microenvironment modulation creates resistance
Solution Approach 1:
The patent applies preliminary action by genetically modifying tumor cells in advance to eliminate CD38 expression before therapeutic intervention. By pre-knocking out the CD38 gene in tumor cells, the invention ensures that when CAR-T cells or other CD38-targeting therapies are administered, the tumor cells cannot mount a resistance response through CD38-mediated mechanisms, thereby preventing resistance development.
Solution Approach 2:
The invention converts the harmful effect of CD38-mediated resistance into a benefit by using CRISPR/Cas9 to create CD38-deficient tumor cells. What was originally a mechanism of resistance (CD38 expression allowing tumor cells to evade therapy) is transformed into a vulnerability (lack of CD38 making tumor cells susceptible to CAR-T cell attack), thereby turning the harmful factor into a therapeutic advantage.
3Reliability
If genetically modified cells are used to target CD38 cancers, then treatment efficacy is enhanced, but complexity of genetic modification increases
Solution Approach 1:
The patent introduces an intermediary system (CRISPR/Cas9 gene editing machinery) that simplifies the complex process of genetic modification. Instead of using complicated viral vectors or traditional gene targeting methods, the CRISPR/Cas9 system provides a straightforward, programmable approach to knock out the CD38 gene, thereby reducing the overall complexity of generating genetically modified tumor cells or CAR-T cells while maintaining high treatment efficacy.
Data Source
AI summary
Compositions and methods for editing, e.g., altering a DNA sequence, within a CD38 gene are provided. Compositions and methods for immunotherapy are provided.